Focus topics

Sinovac: doubts on Covid vaccine

As Chinese pharmaceutical manufacturer Sinovac ramps up the output of its Covid vaccine to one billion doses per year, doubts are mounting about the validity of the published efficacy data. Last week, the Brazilian Butantan Institute was still talking about a protective effect of 78 percent; before Christmas, there was talk of it “generating an immune response in 97 percent of cases.” This week it had to retract that figure to a disappointing 50.4 percent. Meanwhile, Sinovac points out that further continuation of the studies is necessary to obtain clear values.

Continue reading now

… and get free access to this Professional Briefing for a month.

Are you already a guest at the China.Table? Log in now


    ‘Politicians’ visits to Taiwan are parts of a larger theater play’
    Foreign countries are courting Xi
    Beijing wants to play neutral role in the Middle East
    Demands of Chinese tourists have changed